Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 153

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION...

PT374 – Personalizing Psychedelic Integration

Psychedelic Brains In A Dish

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting...

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing...

Why Did Psychedelics Relieve My Chronic Pain?

Psychedelics Weekly – Oregon Measure 109: Approaching the Proposed Final Rules

MAPS Wraps Second Phase 3 Trial of MDMA-Assisted Therapy for PTSD

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

Load more

EDITOR PICKS

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©